# Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

> **NCT00731120** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 457 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Vortioxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00731120
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-01
- **Final completion:** 2009-02
- **Target enrollment:** 457 (ACTUAL)
- **Last updated:** 2013-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731120, "Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00731120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*